- Conditions
- Metastatic Neuroendocrine Prostate Cancer
- Interventions
- Antiemetics & antinauseants, GnRH antagonists, Gonadotropin-releasing hormone (GnRH) analogues, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Metoclopramide, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, [177Lu]Lu-PSMA-617, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [68Ga]Ga-PSMA-11
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Omaha, Nebraska • New York, New York + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–1
of 1
matching trial from the local directory fallback.